

Committed to improving health outcomes for cancer patients



General Meeting March 2007

ASX: PGL, NASDAQ: PGLA

Safe Harbour Statement


This presentation contains forward-looking statements that are based on current management expectations. These statements may differ materially from actual future events or results due to certain risks and uncertainties, including without limitation, risks associated with drug development and manufacture, risks inherent in the extensive regulatory approval process mandated by the United States Food and Drug Administration and the Australian Therapeutic Goods Administration, delays in obtaining the necessary approvals for clinical testing, patient recruitment, delays in the conduct of clinical trials, market acceptance of PI-88, PI-166 and other drugs, future capital needs, general economic conditions and other risks and uncertainties detailed from time to time in the Company's filings with the Australian Stock Exchange and the United States Securities and Exchange Commission. Moreover, there can be no assurance that clinical data will remain scientifically, medically or commercially relevant or that others will not independently develop similar products or processes or design around patents owned or licensed by the Company, or that patents owned or licensed by the Company will provide meaningful protection or competitive advantages.



Content

▶ **Milestones since the AGM**

▶ **The Road Ahead**





PI-88 Preliminary Phase II data



PI-88 Phase II Post-Resection Liver Cancer Trial



Preliminary Data

Liver cancer patients

Stage 1
(168 patients)

No treatment

58 patients

160 mg PI-88

56 patients

250 mg PI-88

54 patients

Higher dropout rate


(12 patients)

Efficacy comparison:


1. Disease free rate (%)
2. Disease free survival (time to recurrence)




PI-88 Phase II post-resection liver cancer timeline




Risk of Recurrence at 30 Weeks



Improvement in Disease-Free Survival (Preliminary Results)



Timeline to First Registration – Liver Cancer





Progen's Future Milestones



Focus on Speed to Market for PI-88

Phase III trial to start second half 2007

- ▶ Engage international CRO
- ▶ Expand PhIII team and clinical advisory board
- ▶ Complete manufacture 150,000 doses of PI-88
- ▶ Submit Ph III trial protocols for regulatory approvals
- ▶ Recruit prospective clinical centres



Progen's Future: Realising the Potential

► Key short term value drivers

- Phase final II liver data release
- SPA approval
- Phase III trial launch

1. Focus on speed to market for PI-88 for value optimisation

2. Continue to expand our 300+ compound pipeline with our drug discovery program


3. Expand our pipeline through in-licensing products and pursuing M&A opportunities



Key 2007 Milestones

▶ Phase II post-resection liver cancer data	CY07Q1	Completed
▶ Long term toxicology study completed	CY07Q1	Completed
▶ API Manufacture completed for Phase III trial	CY07Q1	On track
▶ International CRO selected for Phase III	CY07Q1	On track
▶ Final Phase II post-resection liver cancer data	CY07Q2	On track
▶ Phase II lung cancer data	CY07Q2	CY07Q3
▶ SPA process completed with the FDA	CY07Q2	CY07Q3
▶ Phase III trial launched	CY07Q2	CY07Q3
▶ Lead preclinical candidate chosen	CY07Q3	On track
▶ Melanoma Phase II recruitment completed	CY07Q4	On track
▶ Prostate Phase II recruitment completed	CY07Q4	On track





Committed to improving health outcomes for cancer patients



Financials and capital structure

- ▶ Current cash position (Feb 2007) ~AUD \$33M
- ▶ Market capitalization (Mar 14 2007) ~AUD \$290M
- ▶ Total shares on issue 45,832,484
- ▶ Unquoted employee options 647,000

